Patriot Financial Group Insurance Agency LLC Boosts Position in Merck & Co., Inc. $MRK

Patriot Financial Group Insurance Agency LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 114.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,332 shares of the company’s stock after acquiring an additional 11,399 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Merck & Co., Inc. were worth $2,566,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the fourth quarter worth approximately $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MRK shares. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. CICC Research started coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Finally, Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $128.72.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Merck & Co., Inc. Stock Down 0.2%

Shares of MRK opened at $128.35 on Monday. The business’s 50 day moving average is $116.08 and its 200 day moving average is $114.43. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $128.78. The company has a market capitalization of $316.99 billion, a PE ratio of 36.15, a price-to-earnings-growth ratio of 2.89 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s payout ratio is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.